SNTI News and Press, Senti Biosciences Inc. From 01/05/24

– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 – – Anticipated cost savings, which includes an approximately 37% ...

2023-12-22 12:23:57 ET DENVER, Colo., Dec. 22, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Royalty Management Holding Corp (NASDAQ: RMCO), Senti Biosciences Inc (NASDAQ: SNTI), Polished.com Inc...

2023-12-22 09:51:52 ET DENVER, Colo., Dec. 22, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Royalty Management Holding Corp (NASDAQ: RMCO), Senti Biosciences Inc (NASDAQ: SNTI), Cidara Therapeutics Inc...

– First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – – SENTI-202 is a potential first-in-class off-the-shelf CAR-NK cell ...

2023-11-14 02:32:14 ET More on Senti Biosciences Senti stock soars 175% on Chinese development deal for cancer drug Seeking Alpha’s Quant Rating on Senti Biosciences Historical earnings data for Senti Biosciences Financial information for Senti Bioscie...

– IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 – – Established new strategic collaboration with Celest Therapeutics for clinical development of SENTI-301A to treat liver cancer in China – ...

2023-11-12 01:45:00 ET Summary Eccogene out-licenses global rights for its GLP-1 agonist to AstraZeneca in a $2 billion deal. Biotheus sells ex-China rights for a bispecific antibody candidate to BioNTech for $55 million upfront. WuXi XDC conducts a $500 million Hong Kong IPO ...

2023-11-09 14:44:58 ET Penny stocks , those listed at under $5 per share, are the wild west of the stock market. They’re the ones your typical market newbie brags about at family reunions, boasting he turned spare change into a mini-windfall. Like lottery tickets, they offer the ...

2023-11-09 09:40:22 ET DENVER, Colo., Nov 9, 2023 ( www.247marketnews.com )- We covered Senti Biosciences Inc. (NASDAQ: SNTI) on Tuesday, following its new strategic collaboration with Celest Therapeutics news, when it was trading at $0.5903. Senti Biosciences is now trading at $0.7...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...